Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density lipoprotein receptor (LDLR) protein levels and function. Loss of PCSK9 increases LDLR levels in liver and reduces plasma LDL cholesterol (LDLc), whereas excess PCSK9 activity decreases liver LDLR levels and increases plasma...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Frank-Kamenetsky, Maria, Grefhorst, Aldo, Anderson, Norma N., Racie, Timothy S., Bramlage, Birgit, Akinc, Akin, Butler, David, Charisse, Klaus, Dorkin, Robert, Fan, Yupeng, Gamba-Vitalo, Christina, Hadwiger, Philipp, Jayaraman, Muthusamy, John, Matthias, Jayaprakash, K. Narayanannair, Maier, Martin, Nechev, Lubomir, Rajeev, Kallanthottathil G., Read, Timothy, Röhl, Ingo, Soutschek, Jürgen, Tan, Pamela, Wong, Jamie, Wang, Gang, Zimmermann, Tracy, de Fougerolles, Antonin, Vornlocher, Hans-Peter, Langer, Robert, Anderson, Daniel G., Manoharan, Muthiah, Koteliansky, Victor, Horton, Jay D., Fitzgerald, Kevin
Natura: Artigo
Lingua:Inglês
Pubblicazione: National Academy of Sciences 2008
Soggetti:
Biological Sciences
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2575310/
https://ncbi.nlm.nih.gov/pubmed/18695239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0805434105
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi